Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;48(11):987-994.
doi: 10.1055/s-0042-111319. Epub 2016 Aug 5.

All-cause mortality after ERCP

Affiliations

All-cause mortality after ERCP

Evangelos Kalaitzakis. Endoscopy. 2016 Nov.

Abstract

Background and study aims: This study aimed to externally validate a recently developed English model for the prediction of 30-day mortality after endoscopic retrograde cholangiopancreatography (ERCP). Real-world mortality data beyond 30 days post-ERCP are scarce; thus, the study also aimed to develop a prediction model for mortality up to 12 months post-ERCP. Patients and methods: All patients who underwent their first ERCP during a 3-year period (n = 16 478), as identified from the Swedish Hospital Discharge Registry, were linked to the Swedish Death Registry. Factors associated with all-cause mortality up to 12 months post-ERCP were identified by Cox proportional hazards analysis. A prediction model was developed. Results: Post-ERCP mortality was 5 % at 30 days and increased to 11.9 % at 3 months. The English model slightly overpredicted 30-day mortality, which was corrected with recalibration. Discriminant validity of the recalibrated model was very good (c-statistic = 0.82). Independent predictors of medium-term mortality were: emergency admission (hazard ratio [HR] 1.48), cancer (HR 3.79), noncancer co-morbidity (1.33), gallstone-related diagnosis (HR 0.21), and age (HR 4.86 for ≥ 85 years vs. < 55 years). The c-statistic for 3 - 12-month mortality was 0.86 - 0.88. Specific ERCP complication codes were identified in 1.8 % of deaths within 30 days post-ERCP (0.09 % of ERCPs), and 75 % of deaths (18 % of ERCPs) within 1 year post-ERCP were due to cancer. Conclusions: Mortality doubled from 30 days to 3 months post-ERCP, but it was attributed mainly to underlying disease, notably cancer, and infrequently to ERCP-related causes. A previously developed model predicting 30-day mortality was externally validated. A model accurately predicting mortality up to 12 months post-ERCP was developed.

PubMed Disclaimer

Comment in

Publication types

LinkOut - more resources